Levetiracetam Accord

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

levetiracetam

Available from:

Accord Healthcare S.L.U.

ATC code:

N03AX14

INN (International Name):

levetiracetam

Therapeutic group:

Antiepileptics,

Therapeutic area:

Epilepsija

Therapeutic indications:

Levetiracetam je indiciran kot monoterapija pri zdravljenju epileptičnih napadov s sekundarno generalizacijo ali brez nje pri bolnikih od 16. leta starosti z novo diagnosticirano epilepsijo. Levetiracetam, je označeno kot adjunctive terapija:pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev v odrasle, otroke in dojenčke od enega meseca starosti z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo.

Product summary:

Revision: 16

Authorization status:

Pooblaščeni

Authorization date:

2011-10-03

Patient Information leaflet

                                25
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z
lokalnimi predpisi.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Accord Healthcare S.L.U.
World Trade Center, Moll de Barcelona, s/n,
Edifici Est 6ª planta,
08039 Barcelona,
Španija
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/11/712/001-007 (10/20/30/50/60/100/200 tablet v pretisnih omotih
iz PVC-ja/aluminija)
EU/1/11/712/029-031(30/60/100 tablet v enoodmernih pretisnih omotih)
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Levetiracetam Accord 250 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC:
SN:
NN:
26
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI
DVOJNEM TRAKU
ALUMINIJAST/PVC PRETISNI OMOT
1.
IME ZDRAVILA
Levetiracetam Accord 250 mg filmsko obložene tablete
levetiracetam
2.
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Accord
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
DRUGI PODATKI
27
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA Z 10, 20, 30, 50, 60, 100 IN 200 TABLETAMI
1.
IME ZDRAVILA
Levetiracetam Accord 500 mg filmsko obložene tablete
levetiracetam
2.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN
Ena filmsko obložena tableta vsebuje 500 mg levetiracetama.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
10 filmsko obloženih tablet
20 filmsko obloženih tablet
30 filmsko obloženih tablet
50 filmsko obloženih tablet
60 filmsko obloženih tablet
100 filmsko obloženih tablet
200 filmsko obloženih tablet
30 X 1 filmsko obloženih tablet
60X 1 filmsko obloženih tablet
100 X 1 filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
za peroralno uporabo
6.
POSEBNO O
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA 1
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Levetiracetam Accord 250 mg filmsko obložene tablete
Levetiracetam Accord 500 mg filmsko obložene tablete
Levetiracetam Accord 750 mg filmsko obložene tablete
Levetiracetam Accord 1.000 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Levetiracetam Accord 250 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 250 mg levetiracetama.
Levetiracetam Accord 500 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 500 mg levetiracetama.
Levetiracetam Accord 750 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 750 mg levetiracetama.
Pomožna snov z znanimi učinki:
Ena filmsko obložena tableta vsebuje 0,013 mg oranžnega barvila FCF
(E110).
Levetiracetam Accord 1.000 mg filmsko obložene tablete
Ena filmsko obložena tableta vsebuje 1.000 mg levetiracetama.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Filmsko obložena tableta.
Tableto lahko razdelimo na dva enaka odmerka.
Levetiracetam Accord 250 mg filmsko obložene tablete
Bele ali umazano bele, podolgovate, bikonveksne tablete, z vtisnjeno
oznako ‘L 64’ in zarezo na eni
strani ter brez oznak na drugi strani.
Levetiracetam Accord 500 mg filmsko obložene tablete
Rumene, podolgovate, bikonveksne tablete, z vtisnjeno oznako ‘L
65’ in zarezo na eni strani ter brez
oznak na drugi strani.
Levetiracetam Accord 750 mg filmsko obložene tablete
Rožnate, podolgovate, bikonveksne tablete, z vtisnjeno oznako ‘L
66’ in zarezo na eni strani ter brez
oznak na drugi strani.
Levetiracetam Accord 1.000 mg filmsko obložene tablete
Bele ali umazano bele, podolgovate, bikonveksne tablete, z vtisnjeno
oznako ‘L 67’ in zarezo na eni
strani ter brez oznak na drugi strani.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Levetiracetam Accord je indicirano za samostojno zdravljenje
parcialnih napadov s
sekundarno generalizacijo ali brez nje pri odraslih in mladostnikih od
16. leta starosti z na nov
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-06-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-06-2023
Public Assessment Report Public Assessment Report Bulgarian 10-09-2021
Patient Information leaflet Patient Information leaflet Spanish 21-06-2023
Public Assessment Report Public Assessment Report Spanish 10-09-2021
Patient Information leaflet Patient Information leaflet Czech 21-06-2023
Public Assessment Report Public Assessment Report Czech 10-09-2021
Patient Information leaflet Patient Information leaflet Danish 21-06-2023
Public Assessment Report Public Assessment Report Danish 10-09-2021
Patient Information leaflet Patient Information leaflet German 21-06-2023
Public Assessment Report Public Assessment Report German 10-09-2021
Patient Information leaflet Patient Information leaflet Estonian 21-06-2023
Public Assessment Report Public Assessment Report Estonian 10-09-2021
Patient Information leaflet Patient Information leaflet Greek 21-06-2023
Public Assessment Report Public Assessment Report Greek 10-09-2021
Patient Information leaflet Patient Information leaflet English 21-06-2023
Public Assessment Report Public Assessment Report English 10-09-2021
Patient Information leaflet Patient Information leaflet French 21-06-2023
Public Assessment Report Public Assessment Report French 10-09-2021
Patient Information leaflet Patient Information leaflet Italian 21-06-2023
Public Assessment Report Public Assessment Report Italian 10-09-2021
Patient Information leaflet Patient Information leaflet Latvian 21-06-2023
Public Assessment Report Public Assessment Report Latvian 10-09-2021
Patient Information leaflet Patient Information leaflet Lithuanian 21-06-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-06-2023
Public Assessment Report Public Assessment Report Lithuanian 10-09-2021
Patient Information leaflet Patient Information leaflet Hungarian 21-06-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 21-06-2023
Public Assessment Report Public Assessment Report Hungarian 10-09-2021
Patient Information leaflet Patient Information leaflet Maltese 21-06-2023
Public Assessment Report Public Assessment Report Maltese 10-09-2021
Patient Information leaflet Patient Information leaflet Dutch 21-06-2023
Public Assessment Report Public Assessment Report Dutch 10-09-2021
Patient Information leaflet Patient Information leaflet Polish 21-06-2023
Public Assessment Report Public Assessment Report Polish 10-09-2021
Patient Information leaflet Patient Information leaflet Portuguese 21-06-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 21-06-2023
Public Assessment Report Public Assessment Report Portuguese 10-09-2021
Patient Information leaflet Patient Information leaflet Romanian 21-06-2023
Public Assessment Report Public Assessment Report Romanian 10-09-2021
Patient Information leaflet Patient Information leaflet Slovak 21-06-2023
Public Assessment Report Public Assessment Report Slovak 10-09-2021
Patient Information leaflet Patient Information leaflet Finnish 21-06-2023
Public Assessment Report Public Assessment Report Finnish 10-09-2021
Patient Information leaflet Patient Information leaflet Swedish 21-06-2023
Public Assessment Report Public Assessment Report Swedish 10-09-2021
Patient Information leaflet Patient Information leaflet Norwegian 21-06-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 21-06-2023
Patient Information leaflet Patient Information leaflet Icelandic 21-06-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 21-06-2023
Patient Information leaflet Patient Information leaflet Croatian 21-06-2023
Public Assessment Report Public Assessment Report Croatian 10-09-2021

Search alerts related to this product